{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:16:19Z","timestamp":1794885379555,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04824-w","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:55:32Z","timestamp":1774594532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Christina Dam Bjerregaard","family":"Sillassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Faltermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Leth","family":"Bjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Kj\u00e6r","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne Juul","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Bjerregaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Barkholt","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fr\u00f8lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"G\u00e6de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"4824_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6.","journal-title":"Lancet"},{"key":"4824_CR2","unstructured":"WHO. Obesity and overweight 2025. 1\/9\/2025: The World Health Organization. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"4824_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314. https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009.","journal-title":"Mol Metab"},{"key":"4824_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.celrep.2017.10.008","volume":"21","author":"LJ Lebrun","year":"2017","unstructured":"Lebrun LJ, Lenaerts K, Kiers D, et al. Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep. 2017;21:1160\u20138. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.008.","journal-title":"Cell Rep"},{"key":"4824_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.peptides.2017.11.021","volume":"100","author":"LS Gasbjerg","year":"2018","unstructured":"Gasbjerg LS, Gabe MBN, Hartmann B, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides. 2018;100:173\u201381. https:\/\/doi.org\/10.1016\/j.peptides.2017.11.021.","journal-title":"Peptides"},{"key":"4824_CR6","unstructured":"FDA Approves New Medication for Chronic Weight Management. 2023 Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management."},{"key":"4824_CR7","unstructured":"MOUNJARO (tirzepatide) injection, for subcutaneous use. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf."},{"key":"4824_CR8","unstructured":"Mounjaro. European Medicines Agency. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro#product-info."},{"key":"4824_CR9","unstructured":"FDA Approves First Medication for Obstructive Sleep Apnea. 2024 Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea."},{"key":"4824_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-024-01779-x","author":"L Liu","year":"2024","unstructured":"Liu L, Shi H, Xie M, Sun Y, Nahata MC. Efficacy and safety of tirzepatide versus placebo in overweight or obese\u00a0adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. Int J Clin Pharm. 2024. https:\/\/doi.org\/10.1007\/s11096-024-01779-x.","journal-title":"Int J Clin Pharm"},{"key":"4824_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01621-4","author":"M Ala","year":"2024","unstructured":"Ala M, Mohammad Jafari R, Dehpour AR, Poursalehian M. Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials. Int J Obes (Lond). 2024. https:\/\/doi.org\/10.1038\/s41366-024-01621-4.","journal-title":"Int J Obes (Lond)"},{"key":"4824_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","volume":"86","author":"W Qin","year":"2024","unstructured":"Qin W, Yang J, Ni Y, et al. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 2024;86:70\u201384. https:\/\/doi.org\/10.1007\/s12020-024-03896-z.","journal-title":"Endocrine"},{"key":"4824_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47:677\u201385. https:\/\/doi.org\/10.1038\/s41366-023-01321-5.","journal-title":"Int J Obes (Lond)"},{"key":"4824_CR14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00125-024-06144-1","volume":"67","author":"T Karagiannis","year":"2024","unstructured":"Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67:1206\u201322. https:\/\/doi.org\/10.1007\/s00125-024-06144-1.","journal-title":"Diabetologia"},{"key":"4824_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"key":"4824_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"key":"4824_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2024","unstructured":"Packer M, Zile M, Kramer C, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024;392:427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"4824_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575\u201384. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.005.","journal-title":"Can J Cardiol"},{"key":"4824_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2024.200331","volume":"23","author":"F Perone","year":"2024","unstructured":"Perone F, Spadafora L, Pratesi A, et al. Obesity and cardiovascular disease: risk assessment, physical activity, and management of complications. International Journal of Cardiology Cardiovascular Risk and Prevention. 2024;23:200331. https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200331.","journal-title":"International Journal of Cardiology Cardiovascular Risk and Prevention"},{"key":"4824_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation. 2021;143:1157\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050686.","journal-title":"Circulation"},{"key":"4824_CR21","unstructured":"WHO. Cardiovascular diseases (CVDs) 2025. 25\/9\/2025: World Health Organization. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"4824_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1593134","volume":"16","author":"Q Tian","year":"2025","unstructured":"Tian Q, Song Y, Deng Y, Lin S. Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1593134. https:\/\/doi.org\/10.3389\/fendo.2025.1593134.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4824_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4824_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-094947","volume":"15","author":"CDB Sillassen","year":"2025","unstructured":"Sillassen CDB, Petersen JJ, Kamp CB, et al. Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. BMJ Open. 2025;15:e094947. https:\/\/doi.org\/10.1136\/bmjopen-2024-094947.","journal-title":"BMJ Open"},{"key":"4824_CR25","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane; 2024. Available from: www.training.cochrane.org\/handbook."},{"key":"4824_CR26","unstructured":"Guideline for good clinical practice E6(R2): Committee for Human Medicinal Products European Medicines Agency; 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf."},{"key":"4824_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-90","volume":"10","author":"F Keus","year":"2010","unstructured":"Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol. 2010;10:90. https:\/\/doi.org\/10.1186\/1471-2288-10-90.","journal-title":"BMC Med Res Methodol"},{"key":"4824_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120. https:\/\/doi.org\/10.1186\/1471-2288-14-120.","journal-title":"BMC Med Res Methodol"},{"key":"4824_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"4824_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/sim.4780060325","volume":"6","author":"DL DeMets","year":"1987","unstructured":"DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6:341\u201350. https:\/\/doi.org\/10.1002\/sim.4780060325.","journal-title":"Stat Med"},{"key":"4824_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/1536867x1401400204","volume":"14","author":"JW Hardin","year":"2014","unstructured":"Hardin JW, Hilbe JM. Estimation and testing of binomial and beta-binomial regression models with and without zero inflation. Stata J. 2014;14:292\u2013303. https:\/\/doi.org\/10.1177\/1536867x1401400204.","journal-title":"Stata J"},{"key":"4824_CR32","unstructured":"StataCorp. Stata statistical software: Release 18 College Station, TX: StataCorp LLC; 2023. Available from: http:\/\/www.stata.com."},{"key":"4824_CR33","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA) [pdf] 2017.[1\u2013119 pp.]: Copenhagen: Copenhagen Trial Unit. Available from: http:\/\/ctu.dk\/wp-content\/uploads\/2021\/03\/2017-10-10-TSA-Manual-ENG_ER.pdf."},{"key":"4824_CR34","unstructured":"TSA - trial sequential analysis. Copenhagen Trial Unit; Available from: http:\/\/www.ctu.dk\/tsa\/."},{"key":"4824_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. Grade guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380\u20132. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.09.011.","journal-title":"J Clin Epidemiol"},{"key":"4824_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"4824_CR37","first-page":"677","volume":"169","author":"HJ Sch\u00fcnemann","year":"2003","unstructured":"Sch\u00fcnemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169:677\u201380.","journal-title":"CMAJ"},{"key":"4824_CR38","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/s0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180\u201393. https:\/\/doi.org\/10.1016\/s0140-6736(18)32260-8.","journal-title":"Lancet"},{"key":"4824_CR39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22:938\u201346. https:\/\/doi.org\/10.1111\/dom.13979.","journal-title":"Diabetes Obes Metab"},{"key":"4824_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6.","journal-title":"Lancet"},{"key":"4824_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327:534\u201345. https:\/\/doi.org\/10.1001\/jama.2022.0078.","journal-title":"JAMA"},{"key":"4824_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/dom.14572","volume":"24","author":"K Furihata","year":"2022","unstructured":"Furihata K, Mimura H, Urva S, Oura T, Ohwaki K, Imaoka T. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022;24:239\u201346. https:\/\/doi.org\/10.1111\/dom.14572.","journal-title":"Diabetes Obes Metab"},{"key":"4824_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/s2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10:418\u201329. https:\/\/doi.org\/10.1016\/s2213-8587(22)00085-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4824_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"4824_CR45","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1007\/s12325-023-02536-8","volume":"40","author":"P Feng","year":"2023","unstructured":"Feng P, Sheng X, Ji Y, et al. A phase 1 multiple dose study of tirzepatide in Chinese patients with type 2 diabetes. Adv Ther. 2023;40:3434\u201345. https:\/\/doi.org\/10.1007\/s12325-023-02536-8.","journal-title":"Adv Ther"},{"key":"4824_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X.","journal-title":"Lancet"},{"key":"4824_CR47","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29:2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"key":"4824_CR48","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","volume":"332","author":"L Zhao","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024;332:551\u201360. https:\/\/doi.org\/10.1001\/jama.2024.9217.","journal-title":"JAMA"},{"key":"4824_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","volume":"13","author":"T Kadowaki","year":"2025","unstructured":"Kadowaki T, Kiyosue A, Shingaki T, Oura T, Yokote K. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2025;13:384\u201396. https:\/\/doi.org\/10.1016\/S2213-8587(24)00377-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4824_CR50","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","volume":"31","author":"CK Martin","year":"2025","unstructured":"Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025;31:3141\u201350. https:\/\/doi.org\/10.1038\/s41591-025-03774-9.","journal-title":"Nat Med"},{"key":"4824_CR51","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","volume":"37","author":"E Ravussin","year":"2025","unstructured":"Ravussin E, Sanchez-Delgado G, Martin CK, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 2025;37:1060-74.e4. https:\/\/doi.org\/10.1016\/j.cmet.2025.03.011.","journal-title":"Cell Metab"},{"key":"4824_CR52","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2213-8587(25)00248-7","volume":"13","author":"L Guo","year":"2025","unstructured":"Guo L, Dong X, Ma J, et al. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13:1015\u201329. https:\/\/doi.org\/10.1016\/S2213-8587(25)00248-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4824_CR53","unstructured":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05963022."},{"key":"4824_CR54","unstructured":"A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus. 2024. [cited 17\/1\/2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04050553."},{"key":"4824_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331:38\u201348. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"key":"4824_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14656566.2024.2436595","volume":"26","author":"M Hamza","year":"2025","unstructured":"Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025;26:31\u201349. https:\/\/doi.org\/10.1080\/14656566.2024.2436595.","journal-title":"Expert Opin Pharmacother"},{"key":"4824_CR57","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1056\/NEJMc2211120","volume":"387","author":"T Dekker","year":"2022","unstructured":"Dekker T. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:1433\u20135. https:\/\/doi.org\/10.1056\/NEJMc2211120.","journal-title":"N Engl J Med"},{"key":"4824_CR58","doi-asserted-by":"publisher","first-page":"S2013","DOI":"10.1097\/hep.0000000000001076","volume":"80","author":"A Index","year":"2024","unstructured":"Index A. Hepatology. 2024;80:S2013\u2013123. https:\/\/doi.org\/10.1097\/hep.0000000000001076.","journal-title":"Hepatology"},{"key":"4824_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S0140-6736(21)01556-7","volume":"398","author":"Department of Error","year":"2021","unstructured":"Department of Error. Lancet. 2021;398:212. https:\/\/doi.org\/10.1016\/S0140-6736(21)01556-7.","journal-title":"Lancet"},{"key":"4824_CR60","doi-asserted-by":"publisher","unstructured":"Tirzepatide: A Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus: Erratum. Am J Ther. 2023; 30: e311, https:\/\/doi.org\/10.1097\/mjt.0000000000001634.","DOI":"10.1097\/mjt.0000000000001634"},{"key":"4824_CR61","doi-asserted-by":"publisher","first-page":"680","DOI":"10.18553\/jmcp.2022.28.6.680","volume":"28","author":"D Nikitin","year":"2022","unstructured":"Nikitin D, Lin GA, Campbell JD, et al. The effectiveness and value of tirzepatide for type 2 diabetes mellitus. J Manag Care Spec Pharm. 2022;28:680\u20134. https:\/\/doi.org\/10.18553\/jmcp.2022.28.6.680.","journal-title":"J Manag Care Spec Pharm"},{"key":"4824_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065736","volume":"13","author":"MM Helsted","year":"2023","unstructured":"Helsted MM, Gasbjerg LS, Vilsb\u00f8ll T, et al. Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial. BMJ Open. 2023;13:e065736. https:\/\/doi.org\/10.1136\/bmjopen-2022-065736.","journal-title":"BMJ Open"},{"key":"4824_CR63","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/jama.2022.11895","volume":"328","author":"A Slomski","year":"2022","unstructured":"Slomski A. Tirzepatide trial demonstrates substantial weight loss. JAMA. 2022;328:322. https:\/\/doi.org\/10.1001\/jama.2022.11895.","journal-title":"JAMA"},{"key":"4824_CR64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clinthera.2023.12.014","volume":"46","author":"J Powell","year":"2024","unstructured":"Powell J, Taylor J. Use of dulaglutide, semaglutide, and tirzepatide in diabetes and weight management. Clin Ther. 2024;46:289\u201392. https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.014.","journal-title":"Clin Ther"},{"key":"4824_CR65","doi-asserted-by":"publisher","unstructured":"Science, Medicine, and the Anesthesiologist (October 2024): Erratum. Anesthesiology. 2024; 141: 1227, https:\/\/doi.org\/10.1097\/aln.0000000000005251.","DOI":"10.1097\/aln.0000000000005251"},{"key":"4824_CR66","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/ch-242134","volume":"87","author":"B Bagherzadeh-Rahmani","year":"2024","unstructured":"Bagherzadeh-Rahmani B, Marzetti E, Karami E, et al. Tirzepatide and exercise training in obesity. Clin Hemorheol Microcirc. 2024;87:465\u201380. https:\/\/doi.org\/10.3233\/ch-242134.","journal-title":"Clin Hemorheol Microcirc"},{"key":"4824_CR67","doi-asserted-by":"publisher","unstructured":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024; 391: 1464-, https:\/\/doi.org\/10.1056\/NEJMx240005.","DOI":"10.1056\/NEJMx240005"},{"key":"4824_CR68","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000001634","volume":"30","author":"E Wong","year":"2023","unstructured":"Wong E, Cope R, Dima L, Nguyen T. Tirzepatide: a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 agonist for the management of type 2 diabetes mellitus: Erratum. Am J Ther. 2023;30:e311. https:\/\/doi.org\/10.1097\/mjt.0000000000001634.","journal-title":"Am J Ther"},{"key":"4824_CR69","unstructured":"Holmberg M. Zepbound From Eli Lilly and Company. Pharm Times. 2025; 91."},{"key":"4824_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16466","author":"M Tang","year":"2025","unstructured":"Tang M, Shi L, Guan D, et al. Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.16466.","journal-title":"Diabetes Obes Metab"},{"key":"4824_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156229","author":"J Yang","year":"2025","unstructured":"Yang J, Turk N, Huynh R, et al. Turning the tide of obesity medicine: tirzepatide in the reversal of lipotoxicity and adipose tissue dysfunction in humans with overweight\/obesity. Metabolism. 2025. https:\/\/doi.org\/10.1016\/j.metabol.2025.156229.","journal-title":"Metabolism"},{"key":"4824_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.mayocp.2024.07.006","volume":"100","author":"R Gutierrez","year":"2025","unstructured":"Gutierrez R, Tama E, Bechenati D, et al. Effect of tirzepatide on body weight and diabetes control in adults with type 1 diabetes and overweight or obesity. Mayo Clin Proc. 2025;100:265\u201375. https:\/\/doi.org\/10.1016\/j.mayocp.2024.07.006.","journal-title":"Mayo Clin Proc"},{"key":"4824_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050668","author":"L Liu","year":"2025","unstructured":"Liu L, Shi H, Xie M, Sun Y, Nahata MC. The Efficacy and Safety of Tirzepatide in Patients with Diabetes and\/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials. Pharmaceuticals. 2025. https:\/\/doi.org\/10.3390\/ph18050668.","journal-title":"Pharmaceuticals"},{"key":"4824_CR74","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae155","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Marathe CS, Rayner CK, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024. https:\/\/doi.org\/10.1210\/endocr\/bqae155.","journal-title":"Endocrinology"},{"key":"4824_CR75","unstructured":"A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05556512."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04824-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04824-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04824-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:07:30Z","timestamp":1778029650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04824-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4824"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04824-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CDBS\u2019s husband has previously been employed at Novo Nordisk, Kalundborg, as \u2018facility manager\u2019 and \u2018sprinkler technician\u2019 (employed from September 1, 2024, to August 31, 2025). PG has received lecture fees for Novo Nordisk, AstraZeneca, Eli Lilly, Bayer, and MSD and has served in Advisory Boards for Novo Nordisk, AstraZeneca, and Bayer. The remaining authors declare no known competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}